Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
KN

NASDAQ · KNTE

Kinnate Biopharma Inc.

Healthcare · Biotechnology

$2.65

Down-$0.01 (-0.38%)

Updated Oct 7, 2026, 7:29 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
124.99M
P/E ratio
-1.1
Dividend yield
0.00%
52-week range
— – —
Volume
2.12M
Avg. volume
417.58K

Price performance · KNTE

KNTE price history

1M range · 0 trading sessions · Daily adjusted prices

KNTE does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest KNTE news

The latest Smart Investors Daily articles mentioning KNTE.

Stock researchCompany · Overview

KNTE research

Overview

Company profile and research snapshot.

Company profile

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$30.00
Implied upside
—
Analysts
—
KNTE recent ratings
DateFirmRatingTarget
Feb 26, 2024StifelHold—
Jan 17, 2024WedbushNeutral—
Sep 19, 2023JefferiesBuy—
Sep 19, 2023HC Wainwright & Co.Neutral—
Sep 19, 2023WedbushNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Mar 1, 2024

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties. The sale of global rights is in furtherance of the Company’s previously announced exploration of strategic alternatives.

GlobeNewswire Inc. · Feb 16, 2024

Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA Corporation ("XOMA") will acquire Kinnate for a price per share of Kinnate common stock ("Kinnate common stock") of between $2.3352 and $2.5879 in cash, consisting of (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of up to $0.2527 per share, plus one non-transferable contingent value right per share, representing the right to receive (a) 100% of the net proceeds payable from any disposition of the Company’s investigational pan-RAF inhibitor, exarafenib, and/or any other pan-RAF inhibitors prior to the closing of the merger transaction and (b) 85% of the net proceeds payable from any disposition of other Kinnate assets entered into prior to, or within one year from, closing and received within five years of closing pursuant to a definitive contingent value rights agreement.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By